Type 2 diabetes
Conditions
Interventions
Test group:On the basis of diet and exercise therapy, insulin pump intensive therapy was used to adjust the hypoglycemic regimen after discharge as degu insulin and liraglutide injection ± oral medici
Control group:On the basis of diet and exercise therapy, insulin pump intensive therapy was used to adjust the hypoglycemic regimen after discharge as basic insulin analogues (insulin degu, insulin gl
Sponsors
The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for type 2 diabetes published by who in 2011: typical diabetic symptoms (overeating, polydipsia, polyuria, weight loss), plus random blood glucose >= 11.1mmol/l or fasting blood glucose >= 7.0mmol/l or ogtt2h blood glucose >= 11.1mmol/l or HbA1c >= 6.5%; Those without typical symptoms of diabetes need to be reexamined and confirmed another day; 2. Meet the expert consensus on short-term intensive insulin therapy for type 2 diabetes (2021 version): fasting blood glucose >= 11.1mmol/l or glycosylated hemoglobin >= 9.0%, or accompanied by obvious hyperglycemia symptoms; 3. GADA (glutamic acid decarboxylase antibody) and other type 1 diabetes related antibodies were negative; 4. BMI >= 25kg/m^2 (or waist circumference>90cm for men and>85cm for women); 5. When the blood glucose reaches the standard, fasting C-peptide >= 1.0ng/ml, and postprandial 2H C-peptide >= 2.5ng/ml; 6. Type 2 diabetic patients with a course of disease <= 5 years 7. the daily dose of insulin during intensive treatment was<60iu.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes mellitus, gestational diabetes mellitus and other special types of diabetes mellitus; 2. Hyperglycemia caused by acute infection, fever and other stress states, acute complications of diabetes (such as hyperosmolar coma), systemic diseases affecting blood glucose (including other endocrine diseases affecting blood glucose, rheumatic diseases, digestive system diseases, etc.), accompanied by severe blood poverty, severe organ dysfunction (such as acute myocardial infarction, heart failure, etc.); Patients with tumor; 3. Lactation and pregnancy; 4. Allergic or intolerant to the drugs used; 5. Effective improvement after strengthening lifestyle measures; 6. Alcoholism, suspected or clear history of drug abuse; 7. Participated in clinical trials of other scientific research drugs or medical devices within 1 month before signing the informed consent, and received treatment of experimental drugs or devices; 8. The researcher believes that there are any factors that affect the subjects' participation in the test or result evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycosylated hemoglobin;Urinary microalbumin/creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| FBG;Blood fat;Blood pressure; | — |
Countries
China
Contacts
Public ContactChen Wenhui
The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine
Outcome results
None listed